tradmap

IOSP Innospec Inc.

$99.59 -0.40%

Data as of close

Basic Materials · Chemicals & Allied Products

Innospec Inc. (IOSP) is a basic materials company in the Chemicals & Allied Products industry, with a market capitalization of $2.5 billion. Shares last traded at $99.59, near their 52-week high. Over the past year the stock is up 36.1%. IOSP trades at a price-to-earnings ratio of 21.04, below the Chemicals & Allied Products median of 38.51. Net profit margin is 6.3%, above the peer median of -4.2%. Revenue declined 3.7% year over year. The shares yield 3.1% in dividends.

Market Cap
$2.5B
Shares Out
24.6M
EPS (TTM)
$4.89
P/E (TTM)*
21.04
P/S Ratio
1.33
P/B Ratio
1.83
Dividend / Share
$3.05
Dividend Yield
3.06%
52-Week High
$101.99
52-Week Low
$65.52
Volume (venue)
9,355
Avg Vol (3m, venue)
8,636.794

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
+0.40%
1M
+2.31%
3M
+14.97%
6M
+30.17%
YTD
+30.15%
1Y
+36.09%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
57.80
SMA (50)
$96.15
SMA (200)
$84.45
Price vs SMA50
+3.58%
Price vs SMA200
+17.93%
ATR (14)
$2.47

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$1.8B
Net Income
$117M
Gross Margin
27.5%
Operating Margin
7.0%
Net Margin
6.3%
Return on Equity
8.7%
Return on Assets
6.3%
Current Ratio
2.78
Debt / Equity
0.00
Revenue Growth (YoY)
-3.7%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

IOSP Dividend History

Dividend / share (TTM)
$3.05
Dividend yield
3.06%
Per-share growth (5y CAGR)
+10.4%
Payout ratio (latest FY)
36%
Fiscal year endTotal dividends paidPer share*Payout ratio
2025-12-31 $42M $1.70 36%
2024-12-31 $39M $1.54 109%
2023-12-31 $35M $1.40 25%
2022-12-31 $32M $1.27 24%
2021-12-31 $29M $1.16 31%
2020-12-31 $26M $1.03 89%
2019-12-31 $25M $1.01 22%
2018-12-31 $22M $0.88 26%
2017-12-31 $19M $0.76 30%
2016-12-31 $16M $0.65 20%
2015-12-31 $15M $0.61 12%
2014-12-31 $13M $0.54 16%

*Per share derived as total dividends paid ÷ weighted diluted shares (SEC EDGAR/XBRL annual cash-flow facts). Reported history — not a forecast of future dividends.

Compare payers on the highest-dividend-yield screener.

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $1.25 2026-08-05
Q1 2026 $1.22 2026-05-08
Q4 2025 (derived) $1.90 2026-02-18
FY 2025 $4.67 2026-02-18
Q3 2025 $0.52 2025-11-05
Q2 2025 $0.94 2025-08-06

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Chemicals & Allied Products peers

IOSP vs 14 industry peers (Chemicals & Allied Products), by market cap. Data as of close

P/E vs peers
21.04 / 38.51 med
-45% discount
P/S vs peers
1.33 / 1.83 med
-27% discount
Net margin vs peers
6.3% / -4.2% med
above median
1–14 of 14
SOLSSolstice Advanced Materials Inc.$9.4B44.562.295.1%-2.68%
BCPCBalchem Corp$5.5B32.465.0015.4%+2.63%
PRMPerimeter Solutions, Inc.$4.6B—6.08-44.9%+0.16%
NGVTIngevity Corp$2.5B46.942.184.7%-0.89%
IOSPInnospec Inc.$2.5B21.041.336.3%-0.40%
OLNOlin Corp$2.1B—0.31-3.3%+3.30%
CCChemours Co$2.0B—0.34-5.2%-2.66%
HUNHuntsman Corp$1.7B—0.31-5.0%+3.32%
ECVTEcovyst Inc.$1.1B—1.27-7.1%-0.49%
FMCFmc Corp$1.0B———+5.09%
SLIStandard Lithium Ltd.$333M———-2.80%
ADURADURO CLEAN TECHNOLOGIES INC.$284M———-5.79%
ACNTASCENT INDUSTRIES CO.$124M—1.48-5.3%-1.36%
CITRCitroTech Inc.$56M—41.43—+3.77%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.